Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5812833 | 0.92 | NOD1 (0.42) | PTGS1GSTK1NOD1GLO1KMT2A | |
| SCHEMBL6657807 | 0.92 | PTGS1 (0.46) | PTGS1GSTK1NOD1GLO1FOLH1 | |
| SCHEMBL6659930 | 0.91 | PTGS1 (0.47) | PTGS1GSTK1NOD1GLO1KMT2A | |
| SCHEMBL6662543 | 0.90 | PTGS1 (0.50) | PTGS1GSTK1NOD1GLO1FOLH1 | |
| SCHEMBL6662744 | 0.87 | PTGS1 (0.47) | PTGS1GSTK1NOD1GLO1FOLH1 | |
| SCHEMBL6656921 | 0.86 | NOD1 (0.41) | PTGS1GSTK1NOD1GLO1KMT2A | |
| SCHEMBL236404 | 0.86 | PTGS1 (0.56) | PTGS1GSTK1NOD1GLO1FOLH1 | |
| SCHEMBL5058672 | 0.86 | PTGS1 (0.56) | PTGS1GSTK1NOD1GLO1FOLH1 | |
| SCHEMBL6664720 | 0.84 | PTGS1 (0.45) | PTGS1GSTK1NOD1GLO1FOLH1 | |
| SCHEMBL246687 | 0.84 | PTGS1 (0.46) | PTGS1GSTK1NOD1GLO1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099762-A1 | COMBINATION THERAPY | THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA (AU) | 2010-04-22 | — | — | US | claimed |
| EP-2076239-A1 | COMBINATION THERAPY | The Mental Health Research Institute of Victoria (AU) | 2009-07-08 | — | — | EP | claimed |
| EP-1539023-A4 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2008-12-31 | — | — | EP | claimed |
| WO-2008049157-A1 | COMBINATION THERAPY | THE MENTAL HEALTH RESEARCH INSTITUTE OF VICTORIA (AU) | 2008-05-02 | — | — | WO | claimed |
| US-20060211628-A1 | Treatment of multiple sclerosis with brain targeted anti oxidant compounds | MOR RESEARCH APPLICATIONS LTD. (IL) | 2006-09-21 | — | — | US | claimed |
| EP-1539023-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2005-06-15 | — | — | EP | claimed |
| EP-0948258-A4 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-12-01 | — | — | EP | claimed |
| US-20040147452-A1 | Non-amphoteric glutathione derivative compositions for tropical application | YU RUEY J | 2004-07-29 | — | — | US | claimed |
| WO-2004012652-A9 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-06-17 | — | — | WO | claimed |
| WO-2004012652-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| WO-2004010968-A1 | NON-AMPHOTERIC GLUTATHIONE DERIVATIVE COMPOSITIONS FOR TOPICAL APPLICATION | YU RUEY J (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1242070-A4 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2003-05-28 | — | — | EP | claimed |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-05-01 | — | — | US | claimed |
| EP-1242070-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-25 | — | — | EP | claimed |
| US-6369106-B1 | SULFHYDRYL CONTAINING COMPOUND AS ANTIOXIDANT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-04-09 | — | — | US | claimed |
| WO-2001047469-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-07-05 | — | — | WO | claimed |
| EP-0948258-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029375-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-09 | — | — | WO | claimed |
| US-11896032-B2 | Agent for improving feed conversion rate, agent for improving survival rate, agent for improving the number of eggs laid by egg-laying hen, and method of giving same to animals, and feed | TSUBAKISANGYO CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| US-5464825-A | Metabolism, transport, protection | CORNELL RESEARCH FOUNDATION, INC. (US) | 1995-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099762-A1 | COMBINATION THERAPY | GPX1, GPX4, GSTA2 | PTGS1 759/4885GSTK1 23/4885NOD1 3803/4885 |
| US-20060211628-A1 | Treatment of multiple sclerosis with brain targeted anti oxidant compounds | TXNRD2, TXN2, TXNRD1 | PTGS1 473/4885GSTK1 36/4885NOD1 4423/4885 |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | GPX4, GPX1, TXN2 | PTGS1 192/4885GSTK1 13/4885NOD1 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.